FINNENCE ▪ THE WIRE FILE
THE WIRE · № 75842
News■ Unclear/unknown
Immorta Bio Pioneers AI-Designed Senolytic Immunotherapy Targeting Diseases of Aging
KINDNews
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN
LAST UPDATE
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Early-stage biotech with planned 2026 clinical entry; no public ticker or data disclosed.
Aging-therapy PR, no validated data yet
CATALYST TO WATCH
Clinical trial initiation
MAIN RISK
Preclinical claims may not replicate
FULL DISPATCH
Breakthrough Nine-Amino-Acid Peptide Designed to Restore the Immune System's Ability to Eliminate Senescent Cells, With Clinical Entry Planned for 2026 MIAMI, Oct. 12, 2026 /PRNewswire/ -- Immorta Bio, Inc., a biotechnology company pioneering therapies targeting fundamental mechanisms of...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Plasma Fractionation Market worth $52.58 billion by 20312026-10-12 14:30 UTC
Plasma Fractionation Market worth $52.58 billion by 20312026-10-12 14:30 UTC
→CORRELATIONshares Healthcare
Prader-Willi Syndrome Market to Expand by 2036 as New Therapeutic Opportunities Address Unmet Clinical Needs2026-10-12 14:31 UTC
Prader-Willi Syndrome Market to Expand by 2036 as New Therapeutic Opportunities Address Unmet Clinical Needs2026-10-12 14:31 UTC
→CORRELATIONshares Healthcare
Raymond Douglas, MD, PhD, Unveils Research on Six-Week Teprotumumab Dosing to Help Protect Hearing2026-10-12 14:42 UTC
Raymond Douglas, MD, PhD, Unveils Research on Six-Week Teprotumumab Dosing to Help Protect Hearing2026-10-12 14:42 UTC
←CORRELATIONshares Healthcare
Viatris: Improved Confidence Drives M&A Action Again (NASDAQ:VTRS)2026-10-12 10:29 UTC
Viatris: Improved Confidence Drives M&A Action Again (NASDAQ:VTRS)2026-10-12 10:29 UTC
←CORRELATIONshares Healthcare
Racura Oncology Cleared to Escalate RC220 to 100 mg/m2 in Phase 1 HARNESS-1 Trial in EGFR-Mutant Non-Small Cell Lung Cancer2026-10-12 11:00 UTC
Racura Oncology Cleared to Escalate RC220 to 100 mg/m2 in Phase 1 HARNESS-1 Trial in EGFR-Mutant Non-Small Cell Lung Cancer2026-10-12 11:00 UTC
←CORRELATIONshares Healthcare
REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 202026-10-12 11:05 UTC
REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 202026-10-12 11:05 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.